Ventilator Assessment - COPD + MDR Acinetobacter + CO2 Narcosis (Day 1 Intubation)

What I Read From the Screen (Mindray SV300, V-SIMV Mode)

Critical Problems to Address Right Now

Revised Ventilator Settings (Suggested)

On Polymyxin B Plan (for MDR/XDR Acinetobacter)

• Polymyxin B loading dose: 2.5 mg/kg IV x1 (infuse over 60 min)
• Maintenance: 2.5-3.0 mg/kg/day in divided doses q12h (infuse over 60 min)
• Duration: 7-10 days for pneumonia

• Polymyxin B does NOT require renal dose adjustment (unlike colistin) - this is a practical advantage in a sick COPD patient
• Combine with a second active agent - options depend on your sensitivity report: sulbactam (ampicillin-sulbactam 3g q4h or high-dose), tigecycline (100-200 mg load, then 50-100 mg q12h), or minocycline (200 mg load, then 100-200 mg q12h). Combination therapy is strongly recommended over monotherapy for XDR Acinetobacter - per Goldman-Cecil: "combination therapy with at least 2 active agents is preferred"
• Watch nephrotoxicity closely - polymyxin B's main risk; monitor urine output and creatinine daily
• If available, cefiderocol (2g q8h over 3h infusion) has emerged as an alternative - the 2023 ATTACK trial (PMID 37182534, Lancet Infect Dis) showed sulbactam-durlobactam was non-inferior to colistin for CRAB - worth checking if sulbactam-durlobactam is accessible in your institution
• Inhaled colistin as an adjunct (not replacement) may improve local lung concentrations for VAP - consider adding nebulized colistin 2 MU q8-12h via inline nebulizer if available

Other Management Reminders

• Sedation/analgesia - Adequate sedation (target RASS -2 to -1) is needed to prevent patient-ventilator dyssynchrony and to allow permissive hypercapnia without distress. Fentanyl infusion preferred over morphine in COPD (less histamine release).
• Bronchodilators via ventilator - Salbutamol MDI via inline spacer or nebulized ipratropium. These will help reduce Ppeak over time.
• Monitor auto-PEEP - Do end-expiratory hold at each vent check.
• Lung mechanics check - Repeat Pplat/compliance calculation after adjusting TV.
• D5 fluids - If this refers to Day 5 of illness, ensure adequate nutrition via NG/NJ - early enteral feeding within 24-48h of intubation.
• ABG in 30-60 min after vent changes to assess pH, PaCO2, PaO2/FiO2.

Disclaimer: This is clinical decision support, not a substitute for bedside assessment. Adjust based on patient's actual weight, ABG, auto-PEEP measurement, and real-time response.

Amikacin as Combination with Polymyxin B - Intermediate Sensitivity: Yes, With Conditions

The Short Answer

Understanding "Intermediate" for Amikacin vs. Acinetobacter

• The susceptible breakpoint for amikacin in Acinetobacter pneumonia is MIC ≤8 µg/mL (using maximal dosing)
• The key PK/PD driver for aminoglycosides is AUC/MIC ratio (concentration-dependent killing)
• At maximal dosing (25-30 mg/kg extended interval, i.e., once-daily high-dose), higher MIC strains can still achieve bactericidal targets in lung epithelial lining fluid (ELF)

• If her amikacin MIC is at the intermediate breakpoint (typically 16-32 µg/mL by CLSI), standard dosing (15 mg/kg) will almost certainly fail
• If MIC is at the lower end of intermediate (e.g., 16), high-dose amikacin (25-30 mg/kg once daily) can potentially achieve the AUC/MIC target of ≥75-100 needed for lung infection
• If MIC is ≥64, don't use it - no dose will overcome this

Goldman-Cecil on Aminoglycosides for Acinetobacter

Practical Approach: How to Use Amikacin in This Setting

The Nephrotoxicity Problem

• Polymyxin B + amikacin = additive nephrotoxicity
• Critically ill patients already have reduced renal reserve
• COPD patients often have baseline renal impairment
• Aminoglycosides are concentration-dependent - once-daily dosing (vs. q8h) actually reduces nephrotoxicity while maximizing efficacy

• Urine output hourly
• Creatinine daily
• If creatinine rises >1.5x baseline or oliguria develops, stop amikacin first

Alternative Combination Partners to Consider

Bottom Line

Disclaimer: Clinical decision support only. Adjust based on full clinical picture, local antibiogram patterns, and renal function.

Updated Ventilator Assessment + Nebulized Amikacin Question

Reading the New Screen (V-SIMV, 1:01 PM - good progress from morning!)

Ventilator Changes Needed

• Worsens hypercapnia (Haldane effect - O2 displaces CO2 from Hb)
• Absorption atelectasis
• O2 toxicity

• Target TV = 240-280 mL

Revised Settings Summary for 40 kg Patient

Nebulized Amikacin - 50% IV + 50% Inhaled Strategy

• Large multicenter RCT (n=850 ICU patients on MV ≥72h)
• Inhaled amikacin 20 mg/kg IBW once daily x3 days significantly reduced VAP incidence (15% vs 22%, p=0.004)
• Also reduced ventilator-associated complications (18% vs 26%)
• This was prophylactic use - your patient already has active infection, so the rationale for treatment is even stronger

• Inhaled antibiotics improved microbiological cure (OR 7.0 in RCTs)
• Improved clinical cure (OR 2.09 in observational data)
• No significant increase in mortality but better cure rates
• Reduced renal impairment (OR 0.65) - key for your patient on polymyxin B
• Subgroup analysis: combined IV + inhaled amikacin showed the best outcomes for mortality, clinical cure, and microbiological cure - this directly validates your proposed strategy

• Lung ELF (epithelial lining fluid) concentrations after nebulization are 10-100x higher than achievable via IV alone
• Overcomes the MIC barrier - even an "intermediate" MIC organism may be susceptible at the supra-MIC concentrations achieved locally in the lung
• Systemic absorption from nebulization is minimal - so nephrotoxicity risk is much lower than full IV dose

Your Proposed Regimen: 50% IV + 50% Nebulized

• Total amikacin dose = 25 mg/kg IBW = 1000 mg (high-dose once daily for MDR)

• Use a vibrating mesh nebulizer (VMN) placed at the Y-piece - NOT a jet nebulizer (VMN delivers 4-6x more drug to the lungs)
• The Mindray SV300 has a Nebulizer button on the right side - use it to pause PEEP delivery during nebulization
• Nebulize during inspiration only if VMN supports it
• Dilute amikacin to 4 mL total volume (500 mg/2 mL + 2 mL saline)
• Duration: 15-20 minutes
• Chest physio after to mobilize secretions
• Monitor SpO2 and bronchospasm during - rare but possible

• Draw peak (30 min post-IV infusion): target 60-80 µg/mL
• Draw trough (just before next dose): target <5 µg/mL
• With only 500 mg IV, peak may be lower (~40-60 range) - this is acceptable if you're adding inhaled top-up
• No TDM needed for nebulized component (systemic absorption negligible)

Safety Watch Points (Polymyxin B + Amikacin Combination)

Bottom Line

Disclaimer: Clinical decision support only - adjust based on TDM results, renal function, and bedside response.